LEVEMIR
ApprovedSmall molecule
Novo NordiskLEVEMIR is one of 36 small molecule programs targeting Type 2 Diabetes. It is currently in Approved.
2
Indications
4
Total Trials
0
Active Trials
35
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
171 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1LEVEMIR
Novo NordiskApproved
NOVOLIN R
Novo NordiskPreclinical
Cysteine Hydrochloride
NovartisPreclinical
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Aurlumyn
BBTG International Inc.
Preclinical
Nexium
DDexcel Pharma Technologies Ltd.
Preclinical
Inderal
WWyeth-Lederle Vaccines
Preclinical
Pravachol
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
SGLT-2 Inhibitor
SSheffield Teaching Hospitals NHS Foundation Trust
Preclinical
Routine Treatment
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Double-blind1 trial
Emergencies1 trial
Sub-Cutaneous Insulin in Hyperglycaemic Emergencies
Withdrawn·—·N/A·NCT00467246
Type 2 Diabetes1 trial
Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes
Terminated·—·Phase 4·NCT02048189·14 enrolled
Regulatory
FDA Approval Timeline[4]
Jun 16, 2005
LEVEMIR
BLA BLA021536
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LEVEMIR. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company